Accentia Biopharmaceuticals, Inc. - Product Pipeline Review - 2012


#138319

97pages

Global Markets Direct

$ 1500

In Stock


Accentia Biopharmaceuticals, Inc. Product Pipeline Review 2012

Global Market Directs pharmaceuticals report, Accentia Biopharmaceuticals, Inc. Product Pipeline Review 2012 provides data on the Accentia Biopharmaceuticals, Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Accentia Biopharmaceuticals, Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from Accentia Biopharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

  • Accentia Biopharmaceuticals, Inc. Brief Accentia Biopharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Accentia Biopharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Accentia Biopharmaceuticals, Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the Accentia Biopharmaceuticals, Inc.s pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Accentia Biopharmaceuticals, Inc.s strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of Accentia Biopharmaceuticals, Inc. in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the Accentia Biopharmaceuticals, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with Accentia Biopharmaceuticals, Inc.. 
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of Accentia Biopharmaceuticals, Inc. and identify potential opportunities in those areas.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Accentia Biopharmaceuticals, Inc. Snapshot 6
Accentia Biopharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Accentia Biopharmaceuticals, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
Accentia Biopharmaceuticals, Inc. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products –  Monotherapy 10
Accentia Biopharmaceuticals, Inc. – Pipeline Products Glance 11
Accentia Biopharmaceuticals, Inc. – Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Accentia Biopharmaceuticals, Inc. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Accentia Biopharmaceuticals, Inc. – Drug Profiles 14
amphotericin B 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
BiovaxID 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
cyclophosphamide 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Accentia Biopharmaceuticals, Inc. – Pipeline Products by Route of Administration 19
Accentia Biopharmaceuticals, Inc. – Pipeline Products By Mechanism of Action 20
Accentia Biopharmaceuticals, Inc. –  Recent Pipeline Updates 21
Accentia Biopharmaceuticals, Inc. – Company Statement 26
Accentia Biopharmaceuticals, Inc. – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Accentia Biopharmaceuticals, Inc., Recent Developments 33
Accentia Biopharmaceuticals, Inc.- Press Release 33
Aug 14, 2012: Biovest Conducts End Of Phase III Review With FDA Of BiovaxID As Consolidation Therapy In Non-Hodgkin’s Lymphoma 33
Jul 30, 2012: Biovest Advances Process Seeking European Marketing Approval For BiovaxID Personalized Lymphoma Vaccine 34
Jul 12, 2012: Biovest’s Eligibility To Seek EU Marketing Approval For BiovaxID Cancer Vaccine As Orphan Drug Confirmed By EMA 35
Jun 20, 2012: Biovest Initiates Formal Regulatory Approval Process For BiovaxID Cancer Vaccine In Europe 35
Jun 07, 2012: NCI Study Demonstrates Significant Overall Survival And Time-To-Next-Treatment Benefits For BiovaxID Cancer Vaccine Following Rituximab-Chemotherapy In Mantle Cell Lymphoma Study 36
May 18, 2012: Biovest Announces Presentation Of BiovaxID Phase II Mantle Cell Lymphoma Clinical Trial Data At ASCO 2012 37
May 16, 2012: Biovest Retains Ferghana Partners To Evaluate Strategic Transactions 38
May 14, 2012: Biovest To Seek Marketing Approval For BiovaxID Personalized Lymphoma Cancer Vaccine In EU 38
May 04, 2012: Accentia Conducts Investigator Meeting In Preparation For New Multiple Sclerosis Drug Study For Cyrevia 40
May 03, 2012: Biovest Announces Presentation Of New Data From Phase II Study Of BiovaxID By National Cancer Institute At ASCO 2012 41
Apr 10, 2012: Biovest To Seek Marketing Approval For BiovaxID Personalized Lymphoma Cancer Vaccine In Canada 41
Feb 16, 2012: Biovest To Present On BiovaxID Personalized Lymphoma Vaccine At San Francisco Cancer Biologics Conference 43
Feb 06, 2012: Biovest Announces Publication Of BiovaxID Personalized Lymphoma Vaccine In HemOnc Today 43
Feb 01, 2012: OneMedPlace Initiates Research Coverage On Biovest And BiovaxID Personalized Lymphoma Vaccine 44
May 31, 2009: Biovest International, Inc. Presents Phase III Results Of BiovaxID 44
Financial Deals Landscape 46
Accentia Biopharmaceuticals, Inc., Deals Summary 46
Accentia Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 48
Venture Financing 48
ActoGeniX Secures $20 Million In Venture Financing 48
Partnerships 51
Biovest International Enters Into Research Agreement With U.S. Army Medical Research Institute 51
Biovest International Enters Into Research Collaboration With Ordway Research Institute 52
Arbor Pharma Enters Into Co-Marketing Agreement With Accentia BioPharma 54
Biovest International Enters Into Distribution Agreement With VWR International 55
SFBC International Enters Into Strategic Alliance With Analytica International 56
PharmaNet Development And Analytica International Form Joint Venture 57
Exaeris Enters Into Co-Promotion Agreement With TEAMM Pharma 58
Licensing Agreements 59
Accentia Enters Into Licensing Agreement With Baxter Healthcare 59
Biovest International Enters Into Licensing Agreement With Revimmune 68
Accentia BioPharma Enters Into Licensing Agreement With Revimmune 77
Accentia BioPharma Amends Licensing Agreement With Mayo Foundation 86
Equity Offering 87
Accentia BioPharma Completes Private Placement Of Units For $0.4 Million 87
Accentia BioPharma Completes Private Placement Of $9 Million 88
Accentia BioPharma Completes Private Placement Of $8 Million 90
Debt Offering 92
Biovest International Completes Second Tranche Private Placement Of 15% Secured Convertible Debentures For $0.3 Million 92
Accentia BioPharma Completes Private Placement Of $9 Million 93
Accentia BioPharma Issues Secured Convertible Debentures For $24.7 Million 94
Accentia BioPharma Issues Secured Convertible Debentures For $25 Million 95

Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

Accentia Biopharmaceuticals, Inc., Key Information 6
Accentia Biopharmaceuticals, Inc., Key Facts 6
Accentia Biopharmaceuticals, Inc. Pipeline by Indication, 2012 8
Accentia Biopharmaceuticals, Inc. Pipeline by Stage of Development, 2012 9
Accentia Biopharmaceuticals, Inc. Monotherapy Products in Pipeline, 2012 10
Accentia Biopharmaceuticals, Inc. Filed, 2012 11
Accentia Biopharmaceuticals, Inc. Phase III, 2012 12
Accentia Biopharmaceuticals, Inc. Phase II, 2012 13
Accentia Biopharmaceuticals, Inc. Pipeline By Route of Administration, 2012 19
Accentia Biopharmaceuticals, Inc. Pipeline Products By Mechanism of Action, 2012 20
Accentia Biopharmaceuticals, Inc. Recent Pipeline Updates, 2012 21
Accentia Biopharmaceuticals, Inc., Subsidiaries 32
Accentia Biopharmaceuticals, Inc., Deals Summary 46
ActoGeniX Secures $20 Million In Venture Financing 48
Biovest International Enters Into Research Agreement With U.S. Army Medical Research Institute 51
Biovest International Enters Into Research Collaboration With Ordway Research Institute 52
Arbor Pharma Enters Into Co-Marketing Agreement With Accentia BioPharma 54
Biovest International Enters Into Distribution Agreement With VWR International 55
SFBC International Enters Into Strategic Alliance With Analytica International 56
PharmaNet Development And Analytica International Form Joint Venture 57
Exaeris Enters Into Co-Promotion Agreement With TEAMM Pharma 58
Accentia Enters Into Licensing Agreement With Baxter Healthcare 59
Biovest International Enters Into Licensing Agreement With Revimmune 68
Accentia BioPharma Enters Into Licensing Agreement With Revimmune 77
Accentia BioPharma Amends Licensing Agreement With Mayo Foundation 86
Accentia BioPharma Completes Private Placement Of Units For $0.4 Million 87
Accentia BioPharma Completes Private Placement Of $9 Million 88
Accentia BioPharma Completes Private Placement Of $8 Million 90
Biovest International Completes Second Tranche Private Placement Of 15% Secured Convertible Debentures For $0.3 Million 92
Accentia BioPharma Completes Private Placement Of $9 Million 93
Accentia BioPharma Issues Secured Convertible Debentures For $24.7 Million 94
Accentia BioPharma Issues Secured Convertible Debentures For $25 Million 95
Accentia Biopharmaceuticals, Inc. Pipeline by Indication, 2012 8
Accentia Biopharmaceuticals, Inc. Pipeline by Stage of Development, 2012 9
Accentia Biopharmaceuticals, Inc. Monotherapy Products in Pipeline, 2012 10
Accentia Biopharmaceuticals, Inc. Pipeline By Route of Administration, 2012 19